The safety of obesity drugs.

Appetite Depressants/adverse effects/pharmacology; Humans; Mood Disorders/chemically induced/psychology; Obesity/drug therapy/psychology; Piperidines/adverse effects/pharmacology; Pyrazoles/adverse effects/pharmacology; Receptor, Cannabinoid, CB1/antagonists & inhibitors

Disciplines :

Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition

Author, co-author :

Van Gaal, Luc F

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Formiguera, Xavier

Language :

English

Title :

The safety of obesity drugs.

Publication date :

2007

Journal title :

Expert Opinion on Drug Safety

ISSN :

1474-0338

eISSN :

1744-764X

Publisher :

Taylor & Francis, United Kingdom

Volume :

Issue :

Pages :

475-6; author reply 477-8

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 08 April 2009

Statistics

Number of views

74 (0 by ULiège)

Number of downloads

2 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

GREENWAY FL, CARUSO MK: Safety of obesity drugs. Expert Opin. Drug Saf. (2005) 4(6):1083-1095.
VAN GAAL LF, RISSANEN AM, SCHEEN AJ, ZIEGLER O, ROSSNER S: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet (2005) 365:1389-1397.
DESPRES JP, GOLAY A, SJÖSTRÖM L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. (2005) 353:2121-2134.
PI-SUNYER FX, ARONNE LJ, HESHMATI HM, DEVIN J, ROSENSTOCK J: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA (2006) 295:761-775.
SCHEEN AJ, FINER N, HOLLANDER P, JENSEN MD, VAN GAAL LF: Efficacy and tolerability of rimonabant in overweight or obese patients with Type 2 diabetes: a randomised controlled study. Lancet (2006) 368:1660-1672.